Related Experiment Video

Updated: Mar 31, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

Nivolumab plus ipilimumab in the treatment of advanced melanoma

Katy K Tsai1, Adil I Daud2

  • 1Helen Diller Comprehensive Cancer Center, University of California, 1600 Divisadero St., Box 1770, San Francisco, CA, 94115, USA. Katy.Tsai@ucsf.edu.

Journal of Hematology & Oncology
|November 1, 2015
PubMed

Insights

Advanced melanoma treatment is improving with immune checkpoint inhibitors. Combination immunotherapy, like blocking CTLA-4 and PD-1, offers a promising new direction for better patient outcomes in this challenging cancer.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Advanced melanoma historically presented limited systemic treatment options.
  • Recent scientific advancements have introduced novel immune checkpoint inhibitors.
  • These innovations have significantly altered the first-line management of advanced melanoma.

Purpose of the Study:

  • To review the impact of recent advancements in immune checkpoint inhibition on advanced melanoma treatment.
  • To highlight the potential of combination immunotherapy in improving treatment outcomes.
  • To discuss the role of combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade.

Main Methods:

  • Review of current scientific literature on advanced melanoma treatment.
  • Analysis of clinical data regarding immune checkpoint inhibitors.
  • Focus on combination immunotherapy strategies, specifically CTLA-4 and PD-1 blockade.

Main Results:

  • Immune checkpoint inhibitors have revolutionized advanced melanoma therapy.
  • Combination immunotherapy, including dual CTLA-4 and PD-1 blockade, shows significant promise.
  • Despite progress, further improvements in treatment efficacy are still needed.

Conclusions:

  • Combination immunotherapy represents a critical advancement in treating advanced melanoma.
  • Targeting both CTLA-4 and PD-1 pathways offers a potential strategy for enhanced patient response.
  • Continued research into combination therapies is essential for overcoming treatment resistance and improving survival rates.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K